摘要
目的比较卡培他滨联合最佳支持治疗与单纯最佳支持治疗在70岁以上晚期胃腺癌患者中的疗效。方法将53例确诊为临床Ⅳ期的70岁以上胃腺癌患者,分成卡培他滨联合最佳支持治疗组和最佳支持治疗组,联合治疗组给予最佳支持治疗和卡培他滨1500mg,2次/d口服,第1～14天,每3周为1周期;最佳支持治疗组仅给予最佳支持治疗。结果联合治疗组CR为6.25%,PR为21.88%,SD为28.13%,总有效率为28.13%,获益率为56.25%,平均生存期为4.8个月,中位生存期为4.5个月,最长生存期13.1个月;最佳支持治疗组平均生存期为2.7个月,中位生存期为2.6个月,最长生存期5.7个月。联合治疗组不良反应均可耐受。结论对于老年IV期胃腺癌患者,卡培他滨联合最佳支持治疗疗效与临床受益优于单纯最佳支持治疗,不良反应均可耐受。
Objective To compare the curative effect between supportive treatment with and without capecitabine for the old age progress gastric carcinoma.Methods Divide the patients diagnosed progress gastric carcinoma into two groups.One group was treated with supportive treatment only.The other group was treated with supportive treatment and capecitabine.The oral administration of capecitabine 1500mg,Bid,d1～14,q3w.Results In the group treated with capecitabine,CR 6.25%,PR 21.88%,SD 28.13%.The effective rate was 28.13%,the clinical control rate was 56.25%;The MST and middle survival time was 4.8 months and 4.5 months,the longest survival was 13.1 months.The MST and middle survival time of the group treated with supportive treatment was 2.7 months and 2.6 months,the longest survival was 5.7 months.Conclusion The curative effect was better in the group with supportive treatment plus capecitabine than in the group with supportive treatment only for the old age progress gastric carcinoma.
出处
《四川医学》
CAS
2010年第10期1511-1512,共2页
Sichuan Medical Journal
关键词
胃腺癌
化疗
卡培他滨
gastric adenocarcinoma
chemotherapy
capecitabine
